BCL3 and kidney disorder: More recently, approaches of targeted therapies for the treatment of inflammatory diseases have been highlighted in kidney disease and other diseases, as well through regulation of the NFκB/NLRP3 axis, regulation of the NFκB signaling pathway by miRNAs to cell-specifically suppress NFκB, and activation of the PI3K/Akt/eNOS pathways or by Bcl3 expression (151–162).